• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

Dr. Fauci’s worst nightmare? We’re living it

By
John Lauerman
John Lauerman
,
Riley Griffin
Riley Griffin
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
John Lauerman
John Lauerman
,
Riley Griffin
Riley Griffin
and
Bloomberg
Bloomberg
Down Arrow Button Icon
June 10, 2020, 11:19 AM ET

Subscribe to Outbreak, a daily roundup of stories on the coronavirus pandemic and its impact on global business, delivered free to your inbox.

The top U.S. Infectious disease specialist called the coronavirus pandemic his “worst nightmare” and warned that the deadly outbreak is far from over.

In just a few months, COVID-19 has devastated countries around the world, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said Tuesday in online comments to the Biotechnology Innovation Organization, an industry group.

Societies, businesses and economies have all suffered as people have sequestered themselves to prevent the spread of the virus and inundation of health systems with severely ill patients. Now that some nations and states are emerging from lockdowns, there’s still a risk that the virus will also return, Fauci said.

The infection won’t “burn itself out with mere public health measures,” he said. “We’re going to need a vaccine for the entire world, billions and billions of doses.”

The U.S. Federal government is planning to fund and undertake large-scale studies of three experimental coronavirus vaccines starting this summer, Dow Jones reported, citing an interview with John Mascola, director of the vaccine research center at NIAID.

Three projects

Moderna Inc.’s final-stage trial is expected to start in July, followed by a test of Oxford University and AstraZeneca PLC’s shot in August. Johnson & Johnson said in a statement that it has accelerated its schedule, with the first human trial now set to begin in the second half of July, instead of the previous schedule for starting trials in September. The trial will include 1,045 healthy adults and will be conducted in the U.S. And Belgium.

With small studies already underway and definitive trials on the verge of starting, it may be possible for some high-risk people to get access to the immunizations under expedited policies from regulators before the end of the year. If the initial signs suggest the injections can protect against infection and no signs of harm emerge, public health officials believe it may be possible to start vaccinating larger groups of people, including health-care workers, by early next year.

Ultimately, even if vaccines work well in trials, the big challenge will be producing and distributing enough of the shots to meet demand from around the world.

Fauci, the head of the infectious disease agency since 1984, has emerged early on as one of the leading voices in the battle by President Donald Trump’s administration against the pandemic. His statements have sometime run counter to the president’s on topics such as when and whether restrictions should be eased, and he and the White House virus task force have recently been sidelined with fewer appearances before the media.

The U.S. Has more coronavirus cases than any other country, with about 2 million, and leads the world in pandemic deaths with more than 112,000. Meanwhile, as states such as New Jersey lift stay-at-home orders, Trump has cheered the revival of U.S. Employment numbers and stock-market gains.

More than 130 vaccines are in development against the coronavirus, according to the World Health Organization.

About the Authors
By John Lauerman
See full bioRight Arrow Button Icon
By Riley Griffin
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.